BioCentury | Jul 14, 2003
Finance

Ebb & Flow

...issued 9.4 million shares at $4 each through Needham & Co. Investors included Quest Diagnostics; WPG Farber...
BioCentury | Jul 3, 2003
Financial News

Vasogen raises $37.5 million

...in a private placement of 9.4 million shares at $4. Investors included Quest Diagnostics ; WPG Farber...
BioCentury | Jan 17, 2000
Finance

Manic Monday

The BioCentury 100 index rocketed 392.6 points (19 percent) to 2417.81 on Monday, the first day of the Chase H&Q Healthcare Conference, with genomics frenzy pacing the sector. Big winners included Genome Therapeutics (GENE), up...
BioCentury | Jul 21, 1997
Emerging Company Profile

Gene Logic Inc.

Gene Logic Inc. Columbia, Md. Technology: Accelerated Target Discovery platform centered on READS system (Restriction Enzyme Analysis of Differentially expressed Sequences) Disease focus: Central nervous system disorders; osteoporosis; prostate, breast and colon cancer; heart failure;...
Items per page:
1 - 4 of 4
BioCentury | Jul 14, 2003
Finance

Ebb & Flow

...issued 9.4 million shares at $4 each through Needham & Co. Investors included Quest Diagnostics; WPG Farber...
BioCentury | Jul 3, 2003
Financial News

Vasogen raises $37.5 million

...in a private placement of 9.4 million shares at $4. Investors included Quest Diagnostics ; WPG Farber...
BioCentury | Jan 17, 2000
Finance

Manic Monday

The BioCentury 100 index rocketed 392.6 points (19 percent) to 2417.81 on Monday, the first day of the Chase H&Q Healthcare Conference, with genomics frenzy pacing the sector. Big winners included Genome Therapeutics (GENE), up...
BioCentury | Jul 21, 1997
Emerging Company Profile

Gene Logic Inc.

Gene Logic Inc. Columbia, Md. Technology: Accelerated Target Discovery platform centered on READS system (Restriction Enzyme Analysis of Differentially expressed Sequences) Disease focus: Central nervous system disorders; osteoporosis; prostate, breast and colon cancer; heart failure;...
Items per page:
1 - 4 of 4